-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Demant A/S (OTCMKTS:WILYY) Vs. Bone Biologics (OTC:BBLG) Financial Analysis
Demant A/S (OTCMKTS:WILYY) Vs. Bone Biologics (OTC:BBLG) Financial Analysis
Demant A/S (OTCMKTS:WILYY – Get Rating) and Bone Biologics (OTC:BBLG – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
Volatility and Risk
Demant A/S has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Get Demant A/S alerts:Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Demant A/S and Bone Biologics, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Demant A/S | 4 | 0 | 1 | 0 | 1.40 |
Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
Insider & Institutional Ownership
7.6% of Bone Biologics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Demant A/S and Bone Biologics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Demant A/S | N/A | N/A | N/A |
Bone Biologics | N/A | 7,587.33% | 7,258.20% |
Earnings and Valuation
This table compares Demant A/S and Bone Biologics' gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Demant A/S | $2.93 billion | 2.26 | $399.82 million | N/A | N/A |
Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
Demant A/S has higher revenue and earnings than Bone Biologics.
Summary
Bone Biologics beats Demant A/S on 5 of the 8 factors compared between the two stocks.
About Demant A/S
(Get Rating)
Demant A/S, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. It operates in two segments, Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products. The Communications segment provides headsets for collaborative work and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
About Bone Biologics
(Get Rating)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Demant A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Demant A/S and related companies with MarketBeat.com's FREE daily email newsletter.
Demant A/S (OTCMKTS:WILYY – Get Rating) and Bone Biologics (OTC:BBLG – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
美國總統特朗普對美國總統特朗普表示,美國總統特朗普將在美國總統選出美國總統選秀會議,但是中國政治人民政治人物的政策是否正確。我們將根據兩家企業的盈利能力、機構擁有權、估值、盈利、股息、風險和分析師建議的實力對比。
Volatility and Risk
波動性和風險
Demant A/S has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Demantra A/S 的貝塔值為 0.52,表明其股價的波動性比標準普爾 500 指數小 48%。相對而言,骨骼生物製劑的 β 值為 0.24,表明其股價的波動性比標準普爾 500 指數低 76%。
Analyst Recommendations
分析師推薦
This is a breakdown of recent ratings and recommmendations for Demant A/S and Bone Biologics, as reported by MarketBeat.com.
根據 MarketBeat.com 報導的,這是對需求 A/S 和骨生物製劑的最近評級和推薦的細分。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Demant A/S | 4 | 0 | 1 | 0 | 1.40 |
Bone Biologics | 0 | 0 | 1 | 0 | 3.00 |
銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
要求的A/S | 4 | 0 | 1 | 0 | 1.40 |
骨生物製劑 | 0 | 0 | 1 | 0 | 3.00 |
Insider & Institutional Ownership
內幕和機構所有權
7.6% of Bone Biologics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
骨骼生物藥股份 7.6% 由機構投資者擁有。強大的機構所有權表明對沖基金、大型基金經理和捐贈基金認為股票有望實現長期增長。
Profitability
盈利
This table compares Demant A/S and Bone Biologics' net margins, return on equity and return on assets.
此表比較了德曼 A/S 和骨生物的淨利潤率、權益回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Demant A/S | N/A | N/A | N/A |
Bone Biologics | N/A | 7,587.33% | 7,258.20% |
淨利潤 | 權益回報率 | 資產回報率 | |
要求的A/S | N/A | N/A | N/A |
骨生物製劑 | N/A | 7,587.33% | 7,258.20% |
Earnings and Valuation
收益及估值
This table compares Demant A/S and Bone Biologics' gross revenue, earnings per share and valuation.
此表比較了 Demantra A/S 和骨生物的總收入、每股盈利和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Demant A/S | $2.93 billion | 2.26 | $399.82 million | N/A | N/A |
Bone Biologics | N/A | N/A | -$1.61 million | N/A | N/A |
總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
要求的A/S | 二百九十三億元 | 2.26 | 三億九百八十二萬元 | N/A | N/A |
骨生物製劑 | N/A | N/A | -一百六十一萬元 | N/A | N/A |
Demant A/S has higher revenue and earnings than Bone Biologics.
DEMT A/S 擁有比骨骼生物製劑更高的收入和收益。
Summary
摘要
Bone Biologics beats Demant A/S on 5 of the 8 factors compared between the two stocks.
與兩種股票相比,骨骼生物製劑在 8 個因素中的 5 個比德曼特 A/S 勝過 Demantra A/S。
About Demant A/S
關於德曼特 A/S
(Get Rating)
(取得評分)
Demant A/S, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. It operates in two segments, Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products. The Communications segment provides headsets for collaborative work and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
Demantra A/S 是一家聽力保健和音頻技術公司,在歐洲、北美、太平洋、亞洲和國際上開發、製造和銷售產品和設備,以增強人們的聽力。它分為兩個部門,聽力保健和通信。聽力保健部門提供聽力植入物和輔助器、聽力保健和診斷產品。通訊部門以 EPOS 品牌為協作工作和遊戲市場提供耳機。該公司前身為威廉·德曼特控股有限公司,並於 2019 年 3 月更名為德曼特 A/S。德曼特 A/S 成立於 1904 年,總部位於丹麥斯默魯姆。
About Bone Biologics
關於骨生物製劑
(Get Rating)
(取得評分)
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
骨生物製劑公司是一家醫療器械公司,專注於使用重組人類蛋白質在脊柱融合中進行骨骼再生。該公司的 NELL-1/DBX 是一種組合產品,它是一種骨刺激性重組蛋白質,可針對骨骼再生提供針對目標的特定控制。它正在開發用於骨架成熟患者的脊柱融合手術的 NELL-1/DBX 融合裝置,用於從 L4-S1 的一個級別上進行退行性椎間盤疾病。該公司的平台技術在脊柱外科,骨科,一般骨科,整形重建,神經外科,介入放射學和運動醫學等外科專科領域的應用。它與加州大學洛杉磯分校技術開發小組簽訂了許可協議,以開發和商業化 NELL-1 用於脊柱融合應用。該公司成立於 2004 年,總部位於馬薩諸塞州伯靈頓。
Receive News & Ratings for Demant A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Demant A/S and related companies with MarketBeat.com's FREE daily email newsletter.
接收Demant A/S每日的最新消息/評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Demant A/S 及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧